Cultivation Capital Life Sciences Fund IV, LP
Raised
$7M
Investors
—
Min Invest
$250,000
AltStreet Analysis
·Generated from EDGAR primary sources
Cultivation Capital Life Sciences Fund IV, LP is a Delaware-organized pooled investment fund targeting longevity and biotechnology investments. This amended Form D reports $6.5M raised under Rule 506(b) and 3(c)(1) exemptions, with a $250K minimum investment. The fund is managed by LLC Life Sciences Fund IV GP, with seven directors including William Schmidt, Sean Morris, Catherine Matthes, Joel Crater, Scott Addonizio, and David Narrow.
This life sciences-focused venture fund employs a standard 506(b) private placement structure common in institutional biotech investing. The $250K minimum positions it at the lower end of institutional fund access thresholds, potentially accommodating qualified clients alongside high-net-worth individuals. The 3(c)(1) exemption suggests a sub-100 investor cap typical of venture capital limited partnerships.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Cultivation Capital LLC
Promoter · Saint Louis, MO
Life Sciences Fund IV GP LLC
Director · Saint Louis, MO
William Schmidt
Director, Promoter · Saint Louis, MO
Sean Morris
Director, Promoter · Saint Louis, MO
Catherine Matthes
Director, Promoter · Saint Louis, MO
Joel Crater
Director, Promoter · Saint Louis, MO
Scott Addonizio
Director, Promoter · Saint Louis, MO
David Narrow
Director, Promoter · Saint Louis, MO
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
